AtriCure Reports Third Quarter 2026 Financial Results
Business Wire•03/11/2026•16:01 ET
0
Key Highlights
- ➤Third-quarter revenue $154.5 million, up 15.0% year over year
- ➤Adjusted EBITDA $26.8 million, up 51% year over year
- ➤Net income $4.1 million versus $0.3 million net loss
- ➤2026 revenue guidance $606 million-$610 million; adjusted EBITDA $91 million-$94 million
- ➤Minimally invasive ablation sales declined as physicians adopted PFA catheters
Expert Statements
Michael Carrel, President and Chief Executive Officer of AtriCure
“Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution.”
Michael Carrel, President and Chief Executive Officer of AtriCure
“Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead.”
Michael Carrel, President and Chief Executive Officer of AtriCure
“We are well positioned to extend our leadership in cardiac surgery and post-operative pain management, creating lasting value for patients and our shareholders.”
* Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year
* Profitability expansion in the Third Quarter 2026, with net income of $4.1 million and adjusted EBITDA of $26.8 million
Get started
Create a free account to read the full story.